Pliant Therapeutics (PLRX) Preferred Stock Liabilities (2019 - 2020)
Pliant Therapeutics (PLRX) reported Preferred Stock Liabilities of $62.5 million for Q1 2020, up 30.29% quarter-over-quarter from $47.9 million in Q4 2019.
Pliant Therapeutics (PLRX) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Pliant Therapeutics (PLRX) has 2 years of Preferred Stock Liabilities data on file, last reported at $62.5 million in Q1 2020.
- Preferred Stock Liabilities for Q1 2020 came in at $62.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2020 was $62.5 million (changed N/A YoY), and the FY2019 annual result was $47.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $62.5 million in Q1 2020 per PLRX's latest filing, from $47.9 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $74.7 million in Q3 2019 and troughed at $47.9 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Pliant Therapeutics | 74.16 Mn | 74.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 62.47 Mn |
| Dec 31, 2019 | 47.95 Mn |
| Sep 30, 2019 | 74.67 Mn |
| Jun 30, 2019 | 73.29 Mn |